NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2014
NIOSH Scientific Information Quality – Peer Review Agenda
Required Elements for Initial Public Posting:
Title: NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2014
Anticipated Date of Dissemination: September 1, 2014
Subject: Hazardous Drug Exposure in Healthcare Settings
Purpose: To provide healthcare workers and healthcare facilities information on hazardous drugs so that proper handling can be performed to reduce worker exposures.
Timing of Review: December 2012
Primary Disciplines or Expertise Needed for Review: toxicology, industrial hygiene, occupational medicine, oncology nursing practices and pharmacy practices
Type of Review: Panel
Number of Reviewers: 4
Reviewers Selected by: NIOSH
Public Nominations Requested for Review Panel: No
Opportunities for the Public to Comment: Publication of a request for public comments
Peer Reviewers Provided with Public Comments Before Their Review: No
Academic and Professional Credentials: PhD, RN, AOCN
Organizational Affiliation: Duke University
Areas of Expertise, Discipline, or Relevant Experience: Oncology Nursing
Recommended by: Scientific or professional association
Academic and Professional Credentials: PhD
Organizational Affiliation: FDA
Areas of Expertise, Discipline, or Relevant Experience: Drug Evaluation
Academic and Professional Credentials: M.D.
Organizational Affiliation: OSHA
Areas of Expertise, Discipline, or Relevant Experience: Occupational Medicine
Academic and Professional Credentials: MD, MPH, DABT
Organizational Affiliation: University of Maryland
Areas of Expertise, Discipline, or Relevant Experience: Occupational Health
Recommended by: NIOSH
Charge to Peer Reviewers:
The NIOSH Hazardous Drug Committee has reviewed all new FDA drug approvals and new drug warnings for the period January 2010 through December 2011. The committee reviewed 28 new drug approvals and 71 drugs with new warnings and identified 42 drugs as potentially hazardous. Of these 42, 3 already have safe handling guidance in the drug package insert. Therefore, 39 drugs were identified for review by the expert panel.
The meeting will be at the Mayflower Hotel in Washington DC, September 13, 2012 and will include the members of the expert panel and NIOSH personnel.
The meeting will provide time for discussion about the individual drugs proposed, and other questions you might have.
We are requesting that, as members of the expert panel, you review the list of drugs that NIOSH suggests be added to the list and provide your evaluations and comments on the Word document provided. Please return your reviews by November 1, 2012 to Barbara MacKenzie at email@example.com.
NIOSH will review all comments from the expert panel and post a list of proposed additions to the Federal Register for public comment. NIOSH will then make decisions about updating the list based on all comments.
The proposed changes to the list will then be placed on the NIOSH Docket.